HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth

Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutralizing antibodies (bNAbs) to protect against infection to date. The high antigenic diversity and dense N-linked glycan armor, which covers nearly the entire HIV-1 envelope protein (Env), are major roadblocks for...

Full description

Saved in:
Bibliographic Details
Published inRetrovirology Vol. 15; no. 1; p. 74
Main Authors van Schooten, Jelle, van Gils, Marit J
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 26.11.2018
BioMed Central
BMC
Subjects
AIDS vaccines
Antibodies
Genetic aspects
HIV infections
Physiological aspects
Prevention
Review
Netherlands
Online AccessGet full text

Cover

More Information
Summary:Despite enormous efforts no HIV-1 vaccine has been developed that elicits broadly neutralizing antibodies (bNAbs) to protect against infection to date. The high antigenic diversity and dense N-linked glycan armor, which covers nearly the entire HIV-1 envelope protein (Env), are major roadblocks for the development of bNAbs by vaccination. In addition, the naive human antibody repertoire features a low frequency of exceptionally long heavy chain complementary determining regions (CDRH3s), which is a typical characteristic that many HIV-1 bNAbs use to penetrate the glycan armor. Native-like Env trimer immunogens can induce potent but strain-specific neutralizing antibody responses in animal models but how to overcome the many obstacles towards the development of bNAbs remains a challenge. Here, we review recent HIV-1 Env immunization studies and discuss strategies to guide strain-specific antibody responses towards neutralization breadth.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1742-4690
1742-4690
DOI:10.1186/s12977-018-0457-7